GT Biopharma, Inc.
AI Executive Summary
AI-powered analysis of 10-Q filing content
GT Biopharma shows severe financial distress with accumulated deficit of $718M, no revenue generation, and significant losses continuing despite reduced R&D spending. The company has undergone substantial equity dilution and faces going concern issues as a pre-revenue biotech burning cash with limited runway.
Red Flags Detected (7)
Zero revenue with $718M accumulated deficit
Massive 170% dilution - common shares increased from 2.2M to 6.1M
Net loss of $26.9M for 9 months despite $22.9M loss on Greenshoe Rights liability
4 more red flags detected
Key Takeaways
Company remains pre-revenue with massive accumulated losses
Significant equity dilution occurred to raise capital
3 more takeaways
Filing Overview
What This Means
Deteriorating Trend: Conditions are worsening compared to previous filings. This may create opportunities for service providers.
Quarterly Report: Interim filing with unaudited financial data for the quarter.